Sanofi: licensing agreement with RadioMedix and Orano Med

(CercleFinance.com) - Sanofi has signed an exclusive licensing agreement with RadioMedix, a clinical-stage biotech company specialising in the development of radiopharmaceuticals for PET imaging and Targeted Alpha Therapy (TAT).


This agreement is part of Sanofi's efforts to develop innovative treatments for rare cancers, and will address unmet therapeutic needs in oncology. It will help meet unmet therapeutic needs in oncology.

The agreement has also been signed with Orano Med, a French clinical-stage biotechnology company and subsidiary of the Orano Group, specializing in the development of internal vectorised radiotherapies using the unique properties of lead-212 (212Pb) against cancer.

The collaboration between Sanofi, RadioMedix and Orano Med focuses more specifically on the late-stage experimental project AlphaMedix (212Pb-DOTAMTATE). It is currently being evaluated for the treatment of adult patients with progressive unresectable or metastatic neuroendocrine tumors (NETs) expressing the somatostatin receptor, a rare cancer.

Sanofi says that AlphaMedixTM is a targeted alphatherapy composed of a peptide complex targeting the somatostatin receptor and radiolabetized with lead-212 (212Pb), which serves as an in vivo alpha particle generator.


Copyright (c) 2024 CercleFinance.com. All rights reserved.